Clinical Trials Logo
  1. Home
  2. Liver Cancer
  3. NCT05694949
  4. Details
NCT05694949 Clinical Trial

Main Postoperative Complications After COVID-19

Liver Cancer Clinical Trial

Official title:
Main Postoperative Complications After SARS-CoV-2 Infection: A Prospective Cohort Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05694949
Other study ID # MPOC-COVID-19
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date February 1, 2023
Est. completion date February 1, 2024

Study information
Verified date January 2023
Source RenJi Hospital
Contact Diansan Su, MD,PHD
Phone +8618616514088
Email diansansu@yahoo.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 100000
Est. completion date February 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age=18 years; - Patients undergoing any type of elective or confine surgery in operating room; - Informed consent. Exclusion Criteria: - Surgery under local anesthesia (without participation of anesthetist) - Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc - Patients who cannot determine whether they have had SARS CoV-2 infection before surgery - Participating in conflicting clinical study

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (5)
Lead Sponsor Collaborator
RenJi Hospital First Affiliated Hospital of Chongqing Medical University, Second Hospital of Shanxi Medical University, Sichuan Academy of Medical Sciences, The First Affiliated Hospital of Anhui Medical University

Outcome
Type Measure Description Time frame Safety issue
Primary All-cause mortality at 30 days after operation All-cause mortality at 30 days after operation 30 days after surgery
Secondary Main pulmonary complications at 30 days after operation a composite of postoperative pneumonia, acute respiratory distress syndrome (ARDS) and unexpected ventilation 30 days after surgery
Secondary Major Adverse Cardiovascular Events (MACE) a composite of myocardial infarction, new-onset heart failure or cardiogenic shock, deep vein thrombosis (DVT), pulmonary embolism (PE), and cerebrovascular accident (CVA) 30 days after surgery
See also
  Status Clinical Trial Phase
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT03756597 - PAN-study: Pan-Cancer Early Detection Study (PAN)
Recruiting NCT05160740 - Indocyanine Green Molecular Fluorescence Imaging Technique Using in Diagnosis and Treatment of Primary Liver Cancer N/A
Completed NCT01906021 - Study of New Software Used During Ablations N/A
Terminated NCT04589884 - Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment
Recruiting NCT05953337 - Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) N/A
Enrolling by invitation NCT04466124 - Prospective Cohort Study of Liver Cancer Patients Treated With Proton Beam Therapy
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Active, not recruiting NCT02869217 - Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors Phase 1
Completed NCT03059238 - Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure Phase 3
Recruiting NCT02632188 - Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT01388101 - Real-time Diagnosis of Serum LECT 2 in Patient With Liver Cancer Using Electronic Antibody Sensor (e- Ab Sensor) N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Completed NCT00980239 - HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver Phase 1
Completed NCT01042041 - Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer Phase 1
Completed NCT00790569 - Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking N/A
Completed NCT00543777 - Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease Phase 1/Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A